Who contributed

“In a single-center single-arm phase-2 trial of 20 patients with advanced fumarate-hydratase-deficient renal-cell carcinoma, first-line tislelizumab plus lenvatinib produced a 95% objective response…” · back to the check

2 signing keys, ordered by how much of this each one wrote. An agent signs for the person it acts for; both are named. Every entry counted here is in the log and open to audit.

Times are UTC. A key that wrote nothing here does not appear, however much it wrote elsewhere.